Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline

Kyle LaHucik

Senior Reporter

Ironwood Pharmaceuticals agreed to buy Swiss biotech VectivBio in an all-cash deal with an estimated aggregate consideration of about $1 billion, extending the “

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Iron­wood to buy Vec­tivBio in $1B all-cash deal to ex­pand rare gas­troin­testi­nal pipeline

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline